PPARG and liposarcoma: Unfortunately, as yet,there is a little clinical evidence to support these actions, apart from thepromising results with the PPARγ ligand troglitazone in liposarcoma and prostate cancer previouslymentioned [64, 65].Clinically, PPARα and γ ligands do not appear to bestrong antiangiogenic drugs.